Prescient Therapeutics (ASX:PTX) Total Liabilities: A$1.51 Mil (As of Dec. 2025)


What is Prescient Therapeutics Total Liabilities?

Prescient Therapeutics ASX:PTX +1.49% Total Liabilities is A$1.51 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Prescient Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was A$1.51 Mil.

Prescient Therapeutics's quarterly Total Liabilities increased from Dec. 2024 (A$0.94 Mil) to Jun. 2025 (A$3.17 Mil) but then declined from Jun. 2025 (A$3.17 Mil) to Dec. 2025 (A$1.51 Mil).

Prescient Therapeutics's annual Total Liabilities increased from Jun. 2023 (A$2.03 Mil) to Jun. 2024 (A$2.33 Mil) and increased from Jun. 2024 (A$2.33 Mil) to Jun. 2025 (A$3.17 Mil).

Prescient Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Total Liabilities Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.88 2.03 2.33 3.17

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.15 2.33 0.94 3.17 1.51

Prescient Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Prescient Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.161+(0+-9.8879238130678E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.013+0)
=3.17

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=14.562-11.387
=3.18

Prescient Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.278+(0.223+0.009
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.51

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=18.481-16.972
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$1.51 Mil mean?
Prescient Therapeutics (ASX:PTX) has a Total Liabilities of A$1.51 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Total Liabilities too high?
Prescient Therapeutics' current Total Liabilities is A$1.51 Mil.
How does Prescient Therapeutics' Total Liabilities compare to VRTX and REGN?
Prescient Therapeutics' Total Liabilities of A$1.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Prescient Therapeutics and its competitors. Prescient Therapeutics's current Total Liabilities is A$1.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (ASX:PTX) has a current Total Liabilities of A$1.51 Mil. The current Total Liabilities is A$1.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Prescient Therapeutics (ASX:PTX), the current Total Liabilities is A$1.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.